{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:29:04Z","timestamp":1787232544712,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03380-7","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:03:14Z","timestamp":1787230994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Venous thromboembolism prophylaxis in multiple myeloma patients receiving immunomodulatory therapy: a systematic review and meta-analysis"],"prefix":"10.1007","author":[{"given":"Mark","family":"Tippins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Loader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3805-8737","authenticated-orcid":false,"given":"Bareq S.","family":"Al-Lami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Al-Juboori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman O.","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baqir S.","family":"Al-Lami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Corbett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"issue":"1","key":"3380_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos M-V et al (2017) Multiple myeloma. Nat Rev Dis Primers 3(1):17046","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 1(0 1)","key":"3380_CR2","doi-asserted-by":"publisher","first-page":"S177","DOI":"10.1179\/102453312X13336169156933","volume":"17","author":"G Cesarman-Maus","year":"2012","unstructured":"Cesarman-Maus G, Braggio E, Fonseca R (2012) Thrombosis in multiple myeloma (MM). Hematology (United States) 17(Suppl 1(0 1)):S177\u2013S180. https:\/\/doi.org\/10.1179\/102453312X13336169156933","journal-title":"Hematology (United States)"},{"issue":"4","key":"3380_CR3","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","volume":"9","author":"M Carrier","year":"2011","unstructured":"Carrier M, Le Gal G, Tay J, Wu C, Lee AY (2011) Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 9(4):653\u2013663","journal-title":"J Thromb Haemost"},{"issue":"8","key":"3380_CR4","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/leu.2014.60","volume":"28","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos MA, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M et al (2014) Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia 28(8):1573\u20131585","journal-title":"Leukemia"},{"issue":"7","key":"3380_CR5","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/rth2.12411","volume":"4","author":"MW Schoen","year":"2020","unstructured":"Schoen MW, Carson KR, Luo S, Gage BF, Li A, Afzal A et al (2020) Venous thromboembolism in multiple myeloma is associated with increased mortality. Res Pract Thromb Haemost 4(7):1203\u20131210. https:\/\/doi.org\/10.1002\/rth2.12411","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"3380_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/ajh.26806","volume":"98","author":"C Charalampous","year":"2023","unstructured":"Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Dingli D et al (2023) Thrombosis in multiple myeloma: risk estimation by induction regimen and association with overall survival. Am J Hematol 98(3):413\u2013420","journal-title":"Am J Hematol"},{"key":"3380_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/CEOR.S39964","volume":"5","author":"AA Khorana","year":"2013","unstructured":"Khorana AA, Dalal MR, Lin J, Connolly GC (2013) Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clinicoecon Outcomes Res 5:101\u2013108","journal-title":"Clinicoecon Outcomes Res"},{"issue":"8","key":"3380_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70177","volume":"9","author":"G Gerotziafas","year":"2025","unstructured":"Gerotziafas G, Fotiou D, Nijhof I, Ay C, Lecumberri R, Laroca A et al (2025) Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network. Hemasphere 9(8):e70177","journal-title":"Hemasphere"},{"key":"3380_CR9","unstructured":"NCCN. Clinical Practice Guidelines in Oncology (NCCN Guidelines) Version 5.2026: National Comprehensive Cancer Network; 2026 [Accessed 11th of January 2026]. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1445."},{"issue":"Supplement 1","key":"3380_CR10","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/blood-2018-99-116867","volume":"132","author":"GS Calip","year":"2018","unstructured":"Calip GS, Zhou J, Sweiss K, Patel P, Asfaw AA, Lee T et al (2018) Venous thromboembolic prophylaxis following treatment initiation for multiple myeloma. Blood 132(Supplement 1):4693","journal-title":"Blood"},{"key":"3380_CR11","doi-asserted-by":"crossref","unstructured":"Kahale L, Matar C, Tsolakian I, Hakoum M, Yosuico V, Terrenato I, et al (2021) Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents. Cochrane Database Syst Rev ;9.","DOI":"10.1002\/14651858.CD014739"},{"key":"3380_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"3380_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"issue":"7650","key":"3380_CR14","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"3380_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22:153\u2013160","journal-title":"Evid Based Ment Health"},{"issue":"12","key":"3380_CR16","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.4065\/80.12.1568","volume":"80","author":"R Baz","year":"2005","unstructured":"Baz R, Li L, Kottke-Marchant K et al (2005) The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80(12):1568\u20131574. https:\/\/doi.org\/10.4065\/80.12.1568","journal-title":"Mayo Clin Proc"},{"key":"3380_CR17","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1600-0609","volume":"84","author":"M Cini","year":"2010","unstructured":"Cini M, Zamagni E, Valdr\u00e9 L et al (2010) Thalidomide\u2013dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. Eur J Haematol 84:484\u2013492. https:\/\/doi.org\/10.1111\/j.1600-0609","journal-title":"Eur J Haematol"},{"key":"3380_CR18","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/j.1365-2141","volume":"126","author":"M Zangari","year":"2004","unstructured":"Zangari M, Barlogie B, Anaissie E et al (2004) Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126:715\u2013721. https:\/\/doi.org\/10.1111\/j.1365-2141","journal-title":"Br J Haematol"},{"key":"3380_CR19","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/bjh.16653","volume":"190","author":"RF Cornell","year":"2020","unstructured":"Cornell RF, Goldhaber SZ, Engelhardt BG et al (2020) Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. Br J Haematol 190:555\u2013561. https:\/\/doi.org\/10.1111\/bjh.16653","journal-title":"Br J Haematol"},{"key":"3380_CR20","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/ajh.25459","volume":"94","author":"B Pegourie","year":"2019","unstructured":"Pegourie B, Karlin L, Benboubker L et al (2019) Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. Am J Hematol 94:635\u2013640. https:\/\/doi.org\/10.1002\/ajh.25459","journal-title":"Am J Hematol"},{"key":"3380_CR21","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1182\/blood-2018-99-111579","volume":"132","author":"G Campos-Cabrera","year":"2018","unstructured":"Campos-Cabrera G, Mendez-Garcia E, Campos-Cabrera S et al (2018) Rivaroxaban or aspirin as thromboprophylaxis in multiple myeloma. Blood 132:5068. https:\/\/doi.org\/10.1182\/blood-2018-99-111579","journal-title":"Blood"},{"key":"3380_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11239-019-01891-0","volume":"48","author":"Z Sayar","year":"2019","unstructured":"Sayar Z, Czuprynska J, Patel JP et al (2019) What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial. J Thromb Thrombolysis 48:315\u2013322. https:\/\/doi.org\/10.1007\/s11239-019-01891-0","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"3380_CR23","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","volume":"119","author":"A Larocca","year":"2012","unstructured":"Larocca A, Cavallo F, Bringhen S et al (2012) Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 119(4):933\u2013939. https:\/\/doi.org\/10.1182\/blood-2011-03-344333","journal-title":"Blood"},{"issue":"11","key":"3380_CR24","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1080\/10428190600799631","volume":"47","author":"KC Miller","year":"2006","unstructured":"Miller KC, Padmanabhan S, Dimicelli L et al (2006) Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leuk Lymphoma 47(11):2339\u20132343. https:\/\/doi.org\/10.1080\/10428190600799631","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"3380_CR25","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1038\/sj.leu.2403533","volume":"18","author":"MC Minnema","year":"2004","unstructured":"Minnema MC, Breitkreutz I, Auwerda JJA et al (2004) Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 18(12):2044\u20132046. https:\/\/doi.org\/10.1038\/sj.leu.2403533","journal-title":"Leukemia"},{"key":"3380_CR26","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1182\/blood-2021-148062","volume":"138","author":"ML Louzada","year":"2021","unstructured":"Louzada ML, McCurdy A, Shivakumar SP et al (2021) Rivaroxaban for improvement in thromboembolism outcomes in patients with multiple myeloma on lenalidomide-based therapy: the Rithmm feasibility pilot trial. Blood 138:3232. https:\/\/doi.org\/10.1182\/blood-2021-148062","journal-title":"Blood"},{"issue":"8","key":"3380_CR27","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","volume":"29","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Cavo M, Bringhen S et al (2011) Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 29(8):986\u2013993. https:\/\/doi.org\/10.1200\/JCO.2010.31.6844","journal-title":"J Clin Oncol"},{"issue":"1","key":"3380_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT (2021) Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 12(1):55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"3380_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-026-06920-6","author":"S Zhao","year":"2026","unstructured":"Zhao S, Wang Y, Jia J, Bu Q, Chen W (2026) Risk factors for venous thromboembolism in newly diagnosed multiple myeloma patients based on thrombosis prophylaxis. Annals Hematology. https:\/\/doi.org\/10.1007\/s00277-026-06920-6","journal-title":"Annals Hematology"},{"issue":"1","key":"3380_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare4010016","volume":"4","author":"JD Brown","year":"2016","unstructured":"Brown JD, Adams VR (2016) Incidence and risk factors of thromboembolism with multiple myeloma in the presence of death as a competing risk: an empirical comparison of statistical methodologies. Healthcare (Basel) 4(1):16. https:\/\/doi.org\/10.3390\/healthcare4010016","journal-title":"Healthcare (Basel)"},{"issue":"1","key":"3380_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12185-018-2540-1","volume":"109","author":"J Shin","year":"2019","unstructured":"Shin J, Lee JJ, Kim K et al (2019) Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. Int J Hematol 109(1):79\u201390. https:\/\/doi.org\/10.1007\/s12185-018-2540-1","journal-title":"Int J Hematol"},{"issue":"6","key":"3380_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2025.103162","volume":"9","author":"L Vospernik","year":"2025","unstructured":"Vospernik L, Agis H, Ay C et al (2025) Thromboembolism and bleeding in newly diagnosed multiple myeloma: rates, risk profile, and patterns of thromboprophylaxis. Res Pract Thromb Haemost 9(6):103162. https:\/\/doi.org\/10.1016\/j.rpth.2025.103162","journal-title":"Res Pract Thromb Haemost"},{"issue":"7","key":"3380_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102571","volume":"8","author":"OE Fernandez-Vargas","year":"2024","unstructured":"Fernandez-Vargas OE, Amezcua I, Cabello B, Quintana Martinez A, Espinoza R, Cesarman-Maus G (2024) Multiple myeloma: retrospective assessment of routine thromboprophylaxis and utility of thrombotic risk scores. Res Pract Thromb Haemost 8(7):102571. https:\/\/doi.org\/10.1016\/j.rpth.2024.102571","journal-title":"Res Pract Thromb Haemost"},{"key":"3380_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12013","author":"M Alexander","year":"2013","unstructured":"Alexander M et al (2013) Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital. Asia-Pac J Clin Oncol. https:\/\/doi.org\/10.1111\/ajco.12013","journal-title":"Asia-Pac J Clin Oncol"},{"issue":"4","key":"3380_CR35","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00432-021-03693-5","volume":"148","author":"V Leclerc","year":"2022","unstructured":"Leclerc V, Karlin L, Herledan C et al (2022) Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study. J Cancer Res Clin Oncol 148(4):975\u2013984. https:\/\/doi.org\/10.1007\/s00432-021-03693-5","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"3380_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11239-019-01809-w","volume":"48","author":"K Takaishi","year":"2019","unstructured":"Takaishi K, Tsukamoto S, Ohwada C et al (2019) Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis. J Thromb Thrombolysis 48(1):141\u2013148. https:\/\/doi.org\/10.1007\/s11239-019-01809-w","journal-title":"J Thromb Thrombolysis"},{"issue":"13","key":"3380_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11133788","volume":"11","author":"BJ Buckley","year":"2022","unstructured":"Buckley BJ, Lane DA, Calvert P, Zhang J, Gent D, Mullins CD et al (2022) Effectiveness and safety of apixaban in over 3.9 million people with atrial fibrillation: a systematic review and meta-analysis. J Clin Med 11(13):3788. https:\/\/doi.org\/10.3390\/jcm11133788","journal-title":"J Clin Med"},{"key":"3380_CR38","unstructured":"Wang C, Luo C, Primeaux B (2025) Safety and Efficacy of Direct Oral Anticoagulants as Thromboprophylaxis in Patients With Multiple Myeloma Receiving a Lenalidomide-Based Induction Regimen. JHOP. 15(5) https:\/\/www.jhoponline.com\/articles\/safety-and-efficacy-of-direct-oral-anticoagulants-as-thromboprophylaxis-in-patients-with-multiple-myeloma-receiving-a-lenalidomide-based-induction-regimen"},{"issue":"6","key":"3380_CR39","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1111\/bjh.17505","volume":"193","author":"F Covut","year":"2021","unstructured":"Covut F, Ahmed R, Chawla S et al (2021) Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. Br J Haematol 193(6):1213\u20131219. https:\/\/doi.org\/10.1111\/bjh.17505","journal-title":"Br J Haematol"},{"key":"3380_CR40","unstructured":"Gerardo N. Prevention of thromboembolism in patients with multiple myeloma. J Hematol Oncol Pharm. 2018;8(1). Accessed 2026. https:\/\/www.jhoponline.com\/issue-archive\/2018-issues\/jhop-march-2018-vol-8-no-1\/17376-prevention-of-thromboembolism-in-patients-with-multiple-myeloma."},{"key":"3380_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2017-000712","author":"J Burn","year":"2018","unstructured":"Burn J, Pirmohamed M (2018) Direct oral anticoagulants versus warfarin: is new always better than the old? Open Heart. https:\/\/doi.org\/10.1136\/openhrt-2017-000712","journal-title":"Open Heart"},{"issue":"3","key":"3380_CR42","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41375-023-02105-6","volume":"38","author":"EK Mai","year":"2023","unstructured":"Mai EK, Hielscher T, Bertsch U, Salwender HJ, Zweegman S, Raab MS et al (2023) Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients. Leukemia 38(3):640\u2013647. https:\/\/doi.org\/10.1038\/s41375-023-02105-6","journal-title":"Leukemia"},{"issue":"1","key":"3380_CR43","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1182\/hematology.2022000414","volume":"2022","author":"F Covut","year":"2022","unstructured":"Covut F, Sanfilippo KM (2022) Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy. Hematology 2022(1):363\u2013367. https:\/\/doi.org\/10.1182\/hematology.2022000414","journal-title":"Hematology"},{"issue":"26","key":"3380_CR44","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/jco.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L et al (2015) Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 33(26):2863\u20132869. https:\/\/doi.org\/10.1200\/jco.2015.61.2267","journal-title":"J Clin Oncol"},{"issue":"1","key":"3380_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010191","volume":"12","author":"D Fotiou","year":"2020","unstructured":"Fotiou D, Gavriatopoulou M, Terpos E (2020) Multiple myeloma and thrombosis: prophylaxis and risk prediction tools. Cancers 12(1):191. https:\/\/doi.org\/10.3390\/cancers12010191","journal-title":"Cancers"},{"issue":"4","key":"3380_CR46","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1365-2125","volume":"74","author":"C Bond","year":"2012","unstructured":"Bond C, Blenkinsopp A, Raynor DK (2012) Prescribing and partnership with patients. Br J Clin Pharmacol 74(4):581\u2013588. https:\/\/doi.org\/10.1111\/j.1365-2125","journal-title":"Br J Clin Pharmacol"},{"key":"3380_CR47","doi-asserted-by":"publisher","unstructured":"The agree reporting checklist: A tool to improve reporting of Clinical Practice Guidelines. BMJ. 2016 4852. https:\/\/doi.org\/10.1136\/bmj.i4852","DOI":"10.1136\/bmj.i4852"},{"issue":"7","key":"3380_CR48","doi-asserted-by":"publisher","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","volume":"17","author":"A Li","year":"2019","unstructured":"Li A, Wu Q, Luo S et al (2019) Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma. J Natl Compr Canc Netw 17(7):840\u2013847. https:\/\/doi.org\/10.6004\/jnccn.2018.7273","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"3380_CR49","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","volume":"100","author":"E Terpos","year":"2015","unstructured":"Terpos E, Kleber M, Engelhardt M et al (2015) European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica 100(10):1254\u20131266. https:\/\/doi.org\/10.3324\/haematol.2014.117176","journal-title":"Haematologica"},{"issue":"7","key":"3380_CR50","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","volume":"23","author":"D Farge","year":"2022","unstructured":"Farge D, Frere C, Connors JM et al (2022) 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer (ITAC). Lancet Oncol 23(7):e334\u2013e347. https:\/\/doi.org\/10.1016\/S1470-2045(22)00160-7","journal-title":"Lancet Oncol"},{"issue":"16","key":"3380_CR51","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.23.00294","volume":"41","author":"NS Key","year":"2023","unstructured":"Key NS, Khorana AA, Kuderer NM et al (2023) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol 41(16):3063\u20133071. https:\/\/doi.org\/10.1200\/JCO.23.00294","journal-title":"J Clin Oncol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03380-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03380-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03380-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:03:19Z","timestamp":1787230999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03380-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":51,"alternative-id":["3380"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03380-7","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"10 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}